Let the US not buy drugs from India if they're not satisfied: Yusuf Hamied

Interview with Chairman, Cipla Ltd

Regulations in the Indian pharmaceutical sector are under the scanner. These have come under fire after the US Food and Drug Administration (FDA)’s alleged non-compliance by manufacturing units, while they also deal with strict clinical trial guidelines at home, set by the Supreme Court. Yusuf Hamied, chairman of Indian drug manufacturer Cipla Ltd and a veteran in the pharmaceutical industry, talks with Antonita Madonna about the regulatory framework in India and advocates “pragmatic” changes. Edited excerpts: What are your views on the anxiety in the drug ...